The role of second-generation antifungal triazoles for treatment of the endemic mycoses

Current Infectious Disease Reports

Volumn 12, Issue 6, 2010, Pages 471-478

  Freifeld, Alison G ^c   Bariola, J Ryan ^a   Andes, David ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c NONE

Author keywords

Antifungal agents; Blastomycosis; Coccidioidomycosis; Histoplasmosis; Triazoles

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; FLUCONAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; ITRACONAZOLE; POSACONAZOLE; PROTON PUMP INHIBITOR; TACROLIMUS; TRIAZOLE ANTIFUNGAL AGENT; UNCLASSIFIED DRUG; VORICONAZOLE;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; BLASTOMYCES DERMATITIDIS; BLASTOMYCOSIS; BLURRED VISION; BONE DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COCCIDIOIDES IMMITIS; COCCIDIOIDOMYCOSIS; DESQUAMATION; DIARRHEA; DIMORPHIC FUNGAL INFECTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG PENETRATION; DRUG SUBSTITUTION; FEVER; FLU LIKE SYNDROME; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HUMAN; INOTROPISM; KIDNEY DYSFUNCTION; LIVER FAILURE; LOADING DRUG DOSE; LOBAR PNEUMONIA; NAUSEA; PHOTOPHOBIA; PHOTOSENSITIVITY; PNEUMONIA; REVIEW; RIGOR; SIDE EFFECT; SKIN DISEASE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; UNITED STATES; VISION; VISUAL DISORDER; VOMITING;

EID: 77958197709     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-010-0133-0     Document Type: Review

References (59)

1. Centers for Disease Control and Prevention, National Center for Zoonotic, Vector-Borne, and Enteric Diseases: A-Z index for foodborne, bacterial, and mycotic diseases. Available at http://www.cdc.gov/nczved/divisions/dfbmd/ diseases/index.html. Accessed July 2010.
2. LJ Wheat AG Freifeld MB Kleiman, et al. 2007 Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America Clin Infect Dis 45 807 825 10.1086/521259 17806045 (Pubitemid 47580372)
3. SW Chapman WE Dismukes LA Proia, et al. 2008 Clinical practice guidelines for the management of blastomycosis: 2008 update by the infectious Diseases Society of America Clin Infect Dis 46 1801 1812 1:CAS:528:DC%2BD1cXotVagsb0%3D 10.1086/588300 18462107
4. JN Galgiani NM Ampel JE Blair, et al. 2005 Coccidioidomycosis Clin Infect Dis 41 1217 1223 10.1086/496991 16206093 (Pubitemid 41532662)
5. J Wheat S MaWhinney R Hafner, et al. 1997 Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group Am J Med 103 223 232 1:CAS:528:DyaK2sXms1Glu7g%3D 10.1016/S0002-9343(97)00151-4 9316555 (Pubitemid 27413405)
6. PG Pappas RW Bradsher CA Kauffman, et al. 1997 Treatment of blastomycosis with higher doses of fluconazole. The National Institute Of Allergy and Infectious Diseases Mycoses Study Group Clin Infect Dis 25 200 205 1:CAS:528:DyaK2sXmtVyjtbc%3D 10.1086/514539 9332510
7. JM Lestner SA Roberts CB Moore, et al. 2009 Toxicodynamics of itraconazole: implications for therapeutic drug monitoring Clin Infect Dis 49 928 930 1:CAS:528:DC%2BD1MXht1Cqsb7P 10.1086/605499 19681707 This article describes an important study that identifies the upper limit for the itraconazole therapeutic index
8. RK Li MA Ciblak N Nordoff, et al. 2000 In vitro activities of voriconazole, itraconazole, and amphotericin B against blastomyces dermatitidis, coccidioides immitis, and histoplasma capsulatum Antimicrob Agents Chemother 44 1734 1736 1:CAS:528:DC%2BD3cXjs1Olsb4%3D 10.1128/AAC.44.6.1734-1736.2000 10817743 (Pubitemid 30340829)
9. F Sabatelli R Patel PA Mann, et al. 2006 In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts Antimicrob Agents Chemother 50 2009 2015 1:CAS:528:DC%2BD28XlsVOitLc%3D 10.1128/AAC.00163-06 16723559 (Pubitemid 43807519)
10. GM Gonzalez AW Fothergill DA Sutton, et al. 2005 In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi Med Mycol 43 281 284 1:CAS:528:DC%2BD2MXksVejs7w%3D 10.1080/ 13693780500088416 16010855 (Pubitemid 40867502)
11. T Zimmermann RA Yeates H Laufen, et al. 1994 Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole Eur J Clin Pharmacol 46 147 150 1:CAS:528:DyaK2cXlsVWntb0%3D 10.1007/BF00199879 8039534
12. E Dodds Ashley R Lewis J Lewis, et al. 2006 Pharmacology of systemic antifungal agents Clin Infect Dis 43 S28 S39 1:CAS:528:DC%2BD28XnvVOhsro%3D 10.1086/504492 (Pubitemid 44078894)
13. AG Prentice A Glasmacher 2005 Making sense of itraconazole pharmacokinetics J Antimicrob Chemother 56 Suppl 1 i17 i22 1:CAS:528: DC%2BD2MXpsVakurw%3D 10.1093/jac/dki220 16120630 (Pubitemid 41236086)
14. L Purkins N Wood D Kleinermans, et al. 2003 Effect of food on the pharmacokinetics of multiple-dose oral voriconazole Br J Clin Pharmacol 56 Suppl 1 17 23 1:CAS:528:DC%2BD2cXjtFyhtw%3D%3D 10.1046/j.1365-2125.2003.01994.x 14616409 (Pubitemid 37491729)
15. G Krishna A Moton L Ma, et al. 2009 Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers Antimicrob Agents Chemother 53 958 966 1:CAS:528:DC%2BD1MXivF2lur4%3D 10.1128/AAC.01034-08 19075045 The results of this investigation demonstrate the importance of the acidic gastric environment for optimal absorption of posaconazole
16. ES Dodds Ashley JB Varkey G Krishna, et al. 2009 Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers Antimicrob Agents Chemother 53 2960 2964 1:CAS:528:DC%2BD1MXotlajsr4%3D 10.1128/AAC.01178-08 19433558 The authors describe an important investigation of pharmacokinetics for patients unable to take posaconazole by mouth
17. JA Como WE Dismukes 1994 Oral azole drugs as systemic antifungal therapy N Engl J Med 330 263 272 1:STN:280:DyaK2c%2FpsleksQ%3D%3D 10.1056/ NEJM199401273300407 8272088 (Pubitemid 24034139)
18. JM Poirier S Hardy F Isnard, et al. 1997 Plasma itraconazole concentrations in patients with neutropenia: advantages of a divided daily dosage regimen Ther Drug Monit 19 525 529 1:CAS:528:DyaK2sXntlWit7c%3D 10.1097/00007691-199710000-00007 9357095 (Pubitemid 28116829)
19. MA Thiel AS Zinkernagel J Burhenne, et al. 2007 Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis Antimicrob Agents Chemother 51 239 244 1:CAS:528:DC%2BD2sXktVartg%3D%3D 10.1128/AAC.00762-06 17060517 (Pubitemid 46047712)
20. I Lutsar S Roffey P Troke 2003 Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients Clin Infect Dis 37 728 732 10.1086/377131 12942409 (Pubitemid 37100817)
21. L Willems R van der Geest K de Beule 2001 Itraconazole oral solution and intravenous formulations:a review of pharmacokinetics and pharmacodynamics J Clin Pharm Ther 26 159 169 1:CAS:528:DC%2BD3MXlt1yksbw%3D 10.1046/j.1365-2710. 2001.00338.x 11422598 (Pubitemid 32592545)
22. JR Perfect GM Cox RK Dodge WA Schell 1996 In vitro and in vivo efficacies of the azole SCH56592 against cryptococcus neoformans Antimicrob Agents Chemother 40 1910 1913 1:CAS:528:DyaK28Xks12qurY%3D 8843302
23. P Pitisuttithum R Negroni JR Graybill, et al. 2005 Activity of posaconazole in the treatment of central nervous system fungal infections J Antimicrob Chemother 56 745 755 1:CAS:528:DC%2BD2MXhtVKiu7bJ 10.1093/jac/dki288 16135526 (Pubitemid 41487778)
24. E Muhl 2005 Antimycotic drugs under continuous renal replacement therapy Mycoses 48 Suppl 1 56 60 10.1111/j.1439-0507.2005.01113.x 15826289
25. Z Desta X Zhao JG Shin DA Flockhart 2002 Clinical significance of the cytochrome P450 2C19 genetic polymorphism Clin Pharmacokinet 41 913 958 1:CAS:528:DC%2BD38XotlGisbg%3D 10.2165/00003088-200241120-00002 12222994
26. U Theuretzbacher F Ihle H Derendorf 2006 Pharmacokinetic/pharmacodynamic profile of voriconazole Clin Pharmacokinet 45 649 663 1:CAS:528: DC%2BD28Xot1eksL0%3D 10.2165/00003088-200645070-00002 16802848 (Pubitemid 43990568)
27. AE Boyd S Modi SJ Howard, et al. 2004 Adverse reactions to voriconazole Clin Infect Dis 39 1241 1244 10.1086/424662 15486850 (Pubitemid 40169325)
28. J Smith N Safdar V Knasinski, et al. 2006 Voriconazole therapeutic drug monitoring Antimicrob Agents Chemother 50 1570 1572 1:CAS:528: DC%2BD28XjvFOrtrg%3D 10.1128/AAC.50.4.1570-1572.2006 16569888
29. RJ Bruggemann JW Alffenaar NM Blijlevens, et al. 2009 Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents Clin Infect Dis 48 1441 1458 10.1086/598327 19361301 This article is a thorough and clinically useful review of triazole drug interactions
30. MO Gearhart 1994 Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity Ann Pharmacother 28 1177 1181 1:STN:280:DyaK2M7ktlOisw%3D%3D 7841574
31. A Pascual T Calandra S Bolay, et al. 2008 Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes Clin Infect Dis 46 201 211 1:CAS:528:DC%2BD1cXhvVClsbY%3D 10.1086/524669 18171251 This article describes an important clinical study that demonstrates a role for voriconazole therapeutic drug monitoring to optimize efficacy and reduce toxicity (Pubitemid 351269158)
32. SB Girois F Chapuis E Decullier BG Revol 2005 Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis Eur J Clin Microbiol Infect Dis 24 119 130 1:CAS:528:DC%2BD2MXisVCitL8%3D 10.1007/s10096-005-1281-2 15711785 (Pubitemid 40487380)
33. HL Hoffman RC Rathbun 2002 Review of the safety and efficacy of voriconazole Expert Opin Investig Drugs 11 409 429 1:CAS:528: DC%2BD38XitFCmurY%3D 10.1517/13543784.11.3.409 11866669 (Pubitemid 34213394)
34. TJ Pursley IK Blomquist J Abraham, et al. 1996 Fluconazole-induced congenital anomalies in three infants Clin Infect Dis 22 336 340 1:CAS:528:DyaK28Xhs1Ojs7g%3D 8838193
35. DA Stevens M Diaz R Negroni, et al. 1997 Safety evaluation of chronic fluconazole therapy. fluconazole pan-American study group Chemotherapy 43 371 377 1:CAS:528:DyaK2sXlslGit7g%3D 10.1159/000239592 9309372
36. SR Ahmad SJ Singer BG Leissa 2001 Congestive heart failure associated with itraconazole Lancet 357 1766 1767 1:STN:280:DC%2BD3MzjsV2qtA%3D%3D 10.1016/S0140-6736(00)04891-1 11403818 (Pubitemid 32524211)
37. A Freifeld L Proia D Andes, et al. 2009 Voriconazole use for endemic fungal infections Antimicrob Agents Chemother 53 1648 1651 1:CAS:528: DC%2BD1MXksFWkt7w%3D 10.1128/AAC.01148-07 19139290 The authors present a case series suggesting the utility of voriconazole for therapy of endemic fungal infections
38. J Cuellar-Rodriguez RK Avery M Lard, et al. 2009 Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area Clin Infect Dis 49 710 716 1:STN:280:DC%2BD1MrjsVCmug%3D%3D 10.1086/604712 19635026 The authors describe a case series highlighting the rarity of histoplasmosis in solid organ transplant recipients, and the generally excellent outcomes with prompt appropriate antifungal therapy
39. LJ Wheat P Connolly M Smedema, et al. 2006 Activity of newer triazoles against histoplasma capsulatum from patients with AIDS who failed fluconazole J Antimicrob Chemother 57 1235 1239 1:CAS:528:DC%2BD28XmsFyktb0%3D 10.1093/jac/dkl133 16627592 (Pubitemid 44644433)
40. P Connolly LJ Wheat C Schnizlein-Bick, et al. 2000 Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice Antimicrob Agents Chemother 44 2604 2608 1:CAS:528:DC%2BD3cXmvVyqsLc%3D 10.1128/AAC.44.10.2604-2608.2000 10991831
41. A Restrepo A Tobon B Clark, et al. 2007 Salvage treatment of histoplasmosis with posaconazole J Infect 54 319 327 10.1016/j.jinf.2006.05.006 16824608 (Pubitemid 46395016)
42. B Clark R Foster A Tunbridge S Green 2005 A case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole J Infect 51 e177 e180 1:STN:280:DC%2BD2MrlsVCrug%3D%3D 10.1016/j.jinf.2005.01.001 16230202 (Pubitemid 41554867)
43. J Panicker T Walsh N Kamani 2006 Recurrent central nervous system blastomycosis in an immunocompetent child treated successfully with sequential liposomal amphotericin B and voriconazole Pediatr Infect Dis J 25 377 379 10.1097/01.inf.0000207475.89745.51 16567998
44. SM Borgia JD Fuller A Sarabia P El-Helou 2006 Cerebral blastomycosis: a case series incorporating voriconazole in the treatment regimen Med Mycol 44 659 664 1:CAS:528:DC%2BD2sXjt1ensQ%3D%3D 10.1080/13693780600803870 17071562 (Pubitemid 44650518)
45. M Bakleh AJ Aksamit IM Tleyjeh WF Marshall 2005 Successful treatment of cerebral blastomycosis with voriconazole Clin Infect Dis 40 e69 e71 10.1086/429319 15825017
46. JR Bariola P Perry PG Pappas, et al. 2010 Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern era Clin Infect Dis 50 797 804 10.1086/650579 20166817 The authors present a case series of CNS blastomycosis suggesting that lipid amphotericin B followed by a prolonged course of oral azole, preferably voriconazole, is effective in most cases
47. GM Gauthier N Safdar BS Klein DR Andes 2007 Blastomycosis in solid organ transplant recipients Transpl Infect Dis 9 310 317 1:STN:280: DC%2BD2snmtVCntA%3D%3D 10.1111/j.1399-3062.2007.00227.x 17428278 (Pubitemid 350059144)
48. GM Anstead G Corcoran J Lewis, et al. 2005 Refractory coccidioidomycosis treated with posaconazole Clin Infect Dis 40 1770 1776 1:CAS:528: DC%2BD2MXlsFyit7o%3D 10.1086/430303 15909265 (Pubitemid 40799946)
49. DA Stevens A Rendon V Gaona-Flores, et al. 2007 Posaconazole therapy for chronic refractory coccidioidomycosis Chest 132 952 958 1:CAS:528: DC%2BD2sXht1amt7bP 10.1378/chest.07-0114 17573510
50. U Wollina G Hansel I Vennewald, et al. 2009 Successful treatment of relapsing disseminated coccidioidomycosis with cutaneous involvement with posaconazole J Dtsch Dermatol Ges 7 46 49 18759738
51. SJ Antony P Jurczyk L Brumble 2006 Successful use of combination antifungal therapy in the treatment of coccidioides meningitis J Natl Med Assoc 98 940 942 16775917
52. LA Proia AR Tenorio 2004 Successful use of voriconazole for treatment of coccidioides meningitis Antimicrob Agents Chemother 48 2341 10.1128/AAC.48.6. 2341.2004 15155250 (Pubitemid 38691647)
53. D Andes A Pascual O Marchetti 2009 Antifungal therapeutic drug monitoring: established and emerging indications Antimicrob Agents Chemother 53 24 34 1:CAS:528:DC%2BD1MXhs1Klu7c%3D 10.1128/AAC.00705-08 18955533 This article is a useful review of indications for and how to incorporate antifungal therapeutic drug monitoring into clinical practice
54. J Smith D Andes 2008 Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations Ther Drug Monit 30 167 172 1:CAS:528:DC%2BD1cXjslSqtb8%3D 10.1097/FTD.0b013e318167d0e0 18367976 This article is a review of the data available to discern the utility of antifungal therapeutic drug monitoring (Pubitemid 351521643)
55. RM Tucker DW Denning EG Arathoon, et al. 1990 Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations J Am Acad Dermatol 23 3 Pt 2 593 601 1:STN:280:DyaK3M%2FhtVSltg%3D%3D 10.1016/0190- 9622(90)70261-F 2170479
56. TJ Walsh I Raad TF Patterson, et al. 2007 Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial Clin Infect Dis 44 2 12 1:CAS:528:DC%2BD2sXnvVCjtg%3D%3D 10.1086/508774 17143808 (Pubitemid 44968977)
57. EW Cowen JC Nguyen DD Miller, et al. 2010 Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole J Am Acad Dermatol 62 31 37 1:CAS:528: DC%2BC3cXht1ans78%3D 10.1016/j.jaad.2009.09.033 19896749 This report highlights the evolving link between chronic photosensitivity during prolonged voriconazole treatment and squamous cell carcinoma of the skin
58. DD Miller EW Cowen JC Nguyen, et al. 2010 Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity Arch Dermatol 146 300 304 1:CAS:528:DC%2BC3cXks1Sqt70%3D 10.1001/archdermatol. 2009.362 20083676 There may also be a link between chronic photosensitivity during prolonged voriconazole treatment and melanoma
59. • Vadnerkar A, Nguyen MH, Mitsani D, et al.: Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant 2010. Another case report of chronic voriconazole treatment being linked to photosensitivity-related squamous cell carcinoma of the skin.